Skip to content

Follow-up of Adolescents With Autism and Psychotic Symptoms - Psychiatric Co-morbidity and Functional Impairment.

Longitudinal Follow-up of Psychiatric Symptoms and Functioning in Young Adults With Autism.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07427810
Enrollment
53
Registered
2026-02-23
Start date
2026-07-13
Completion date
2027-12-01
Last updated
2026-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Disorder, Schizophrenia and Other Psychotic Disorders

Brief summary

Purpose: To describe level of function, psychotic and psychiatric symptoms in a 10-year follow up of individuals with autism and psychotic symptoms. Method: A case-control study based on a cohort of 48 teenagers with autism established 2013. In this study, 22 participant reported psychotic symptom in self-evaluation questionnaires design for early detection. An additional 5 individuals were recruited in a second round of recruitment in 2019. Three of these individuals reported psychotic symptoms. We aim to recruit individuals with psychotic symptoms and controls from the same cohort without psychotic symptoms. Data will be collected from self-rating scales, clinical evaluation including semi-structured interviews and healthcare journals. The study is primarily descriptive, with group comparison by non-parametric method.

Detailed description

Design: Cohort study. Participants: Participants will be recruited from a previous study cohort established in Region Varmland in 2013, comprising 48 adolescents diagnosed with autism. Psychotic symptoms were identified through self-report in 22 participants. These individuals will be re recruited, along with controls from the same cohort with autism but no psychotic symptoms. In the original study, participants were 15-18 years old at the time of screening, had a diagnosis of autism spectrum disorder (including Asperger's syndrome), and an IQ ≥ 70. An additional 5 individuals were recruited in a second round of recruitment in 2019. Three of these individuals reported psychotic symptoms. Instruments: Youth Psychosis at Risk Questionnaire - Brief Version (YPARQ B). A shortened version of the Youth Psychosis at Risk Questionnaire developed to capture early psychotic symptoms. Prodromal Questionnaire - Brief Version (PQ B): Self report scale assessing psychotic symptoms, including associated distress. Montgomery-Åsberg Depression Rating Scale - Self Report (MADRS S): Swedish self report scale for depressive symptoms. Self evaluation of Negative Symptoms (SNS): Instrument for assessing negative symptoms in psychotic disorders; Swedish translation available. Brief psychiatric rating scale: Structured clinical interview assessing positive and negative psychotic symptoms. Structured Clinical Interview for DSM 5, Clinician Version (SCID 5 CV): Semi structured diagnostic interview. Mini International Neuropsychiatric Interview (MINI): Structured diagnostic interview. Clinical Global Impression - Severity (CGI S): Clinician rated scale for assessing severity of psychiatric illness. Personal and Social Performance Scale (PSP): Clinician rated measure of global functioning in psychotic disorders. Procedure: Approximately ten years after the initial study recruitment, participants will complete PQ B, YPARQ B, SNS, and MADRS-S. Current psychotic symptoms and psychiatric comorbidity will be assessed in clinical evaluation, including BPRS, the psychosis module of SCID 5 CV, and MINI. Socioeconomic status will be assessed. Functional level will be rated using CGI-S and PSP. With participant consent, information regarding psychiatric diagnoses and current pharmacological treatment will be requested from healthcare region. Analysis: Group comparisons will be conducted using non parametric methods. A roughly 1:1 ratio between case and control groups is expected.

Interventions

None. Observational study.

Sponsors

Värmland County Council, Sweden
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* Age 15-18 at enrollment for the original study, * Autism spectrum disorder. * IQ\>70.

Exclusion criteria

\- Non.

Design outcomes

Primary

MeasureTime frame
Number of participants with psychotic diseaseSingle time point at enrollment

Secondary

MeasureTime frame
Number of participants with non-psychotic psychiatric diseaseSingle time point at enrollment
Number of participants with psychotic symptoms without psychotic diseaseSingle time point at enrollment
Number of participants with functional impairmentSingle time point at enrollment

Countries

Sweden

Contacts

CONTACTSverre Wikström, Assoc Prof
sverre.wikstrom@regionvarmland.se+46703456327
PRINCIPAL_INVESTIGATORSverre Wikström

Region Värmland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 3, 2026